Cargando…
Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Association of Psychiatric Pharmacists
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337882/ https://www.ncbi.nlm.nih.gov/pubmed/37448831 http://dx.doi.org/10.9740/mhc.2023.06.167 |
| _version_ | 1785071511248306176 |
|---|---|
| author | VandenBerg, Amy M. |
| author_facet | VandenBerg, Amy M. |
| author_sort | VandenBerg, Amy M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10337882 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | American Association of Psychiatric Pharmacists |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103378822023-07-13 Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” VandenBerg, Amy M. Ment Health Clin Letter to the Editor American Association of Psychiatric Pharmacists 2023-06-28 /pmc/articles/PMC10337882/ /pubmed/37448831 http://dx.doi.org/10.9740/mhc.2023.06.167 Text en © 2023 AAPP. The Mental Health Clinician is a publication of the American Association of Psychiatric Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor VandenBerg, Amy M. Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title | Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title_full | Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title_fullStr | Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title_full_unstemmed | Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title_short | Response to comment on the recently published article “An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use” |
| title_sort | response to comment on the recently published article “an update on recently approved long-acting injectable second-generation antipsychotics: knowns and unknowns regarding their use” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337882/ https://www.ncbi.nlm.nih.gov/pubmed/37448831 http://dx.doi.org/10.9740/mhc.2023.06.167 |
| work_keys_str_mv | AT vandenbergamym responsetocommentontherecentlypublishedarticleanupdateonrecentlyapprovedlongactinginjectablesecondgenerationantipsychoticsknownsandunknownsregardingtheiruse |